Practice guidelines for community-based parenteral anti-infective therapy

被引:88
作者
Williams, DN
Rehm, SJ
Tice, AD
Bradley, JS
Kind, AC
Craig, WA
机构
[1] UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA
[2] PARK NICOLLET MED CTR, MINNEAPOLIS, MN USA
[3] CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA
[4] INFECT LTD, TACOMA, WA USA
[5] CHILDRENS HOSP SAN DIEGO, SAN DIEGO, CA USA
[6] VET AFFAIRS MED CTR, MADISON, WI USA
关键词
D O I
10.1086/515552
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This is the fourth in a series of practice guidelines commissioned by the Infectious Diseases Society of America through its Practice Guidelines Committee, The purpose of this guideline is to provide assistance to clinicians when making decisions on when and how to best administer parenteral antimicrobial therapy, The targeted providers are internists, pediatricians, family practitioners, and other providers of outpatient antiinfective therapy, Criteria for selecting the appropriate patients and settings to deliver therapy in the community are described, Panel members represented experts in adult and pediatric infectious diseases, The guidelines are evidence-based, A standard ranking system is used for the strength of the recommendations and the quality of the evidence cited in the literature reviewed, The document has been subjected to external review by peer reviewers as well as by the Practice Guidelines Committee and was approved by the IDSA Council, An executive summary and tables highlight the major recommendations. The guideline will be listed on the IDSA home page at http://www.idsociety.org.
引用
收藏
页码:787 / 801
页数:15
相关论文
共 100 条
[1]   LACK OF CLINICAL BENEFIT FROM SUBCUTANEOUS TUNNEL INSERTION OF CENTRAL VENOUS CATHETERS IN IMMUNOCOMPROMISED PATIENTS [J].
ANDRIVET, P ;
BACQUER, A ;
NGOC, CV ;
FERME, C ;
LETINIER, JY ;
GAUTIER, H ;
GALLET, CB ;
BRUNBUISSON, C .
CLINICAL INFECTIOUS DISEASES, 1994, 18 (02) :199-206
[2]  
ANTONISKIS A, 1978, WESTERN J MED, V128, P203
[3]  
*ASHP, 1993, AM J HOSP PHARM, V50, P1724
[4]   Antibiotic administration options [J].
Bakken, JS ;
Conlon, CP ;
Smerud, KT ;
Vinen, J ;
Wijlhuizen, TG .
INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 (01) :66-67
[5]  
Barza M, 1996, BRIT MED J, V312, P338
[6]   SINGLE DAILY DOSE TREATMENT OF SEVERE REFRACTORY INFECTIONS WITH CEFTRIAXONE - COST SAVINGS AND POSSIBLE PARENTERAL OUTPATIENT TREATMENT [J].
BAUMGARTNER, JD ;
GLAUSER, MP .
ARCHIVES OF INTERNAL MEDICINE, 1983, 143 (10) :1868-1873
[7]   OUTPATIENT THERAPY OF SERIOUS PEDIATRIC INFECTIONS WITH CEFTRIAXONE [J].
BRADLEY, JS ;
CHING, DK ;
PHILLIPS, SE .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1988, 7 (03) :160-164
[8]   CEFTRIAXONE THERAPY OF BACTERIAL-MENINGITIS - CEREBROSPINAL-FLUID CONCENTRATIONS AND BACTERICIDAL ACTIVITY AFTER INTRAMUSCULAR INJECTION IN CHILDREN TREATED WITH DEXAMETHASONE [J].
BRADLEY, JS ;
FARHAT, C ;
STAMBOULIAN, D ;
BRANCHINI, OG ;
DEBBAG, R ;
COMPOGIANNIS, LS .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (08) :724-728
[9]  
BROWN RB, 1991, REV INFECT DIS, V13, pS147
[10]   AMINOGLYCOSIDE-INDUCED HEARING-LOSS IN HUMANS [J].
BRUMMETT, RE ;
FOX, KE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (06) :797-800